![]() |
Actinium Pharmaceuticals, Inc. (ATNM): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | AMEX
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Actinium Pharmaceuticals, Inc. (ATNM) Bundle
In the cutting-edge world of oncology, Actinium Pharmaceuticals, Inc. (ATNM) emerges as a beacon of hope, revolutionizing cancer treatment through its groundbreaking radioimmunotherapy approach. By strategically blending advanced scientific research, innovative therapeutic technologies, and targeted treatment methodologies, this pioneering company is poised to transform how we understand and combat complex cancer diagnoses. Their comprehensive Business Model Canvas reveals an intricate ecosystem of scientific innovation, collaborative partnerships, and transformative potential that promises to reshape the landscape of personalized cancer care.
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Key Partnerships
Strategic Collaborations with Academic Research Institutions
As of 2024, Actinium Pharmaceuticals maintains research partnerships with the following academic institutions:
Institution | Collaboration Focus | Year Established |
---|---|---|
Memorial Sloan Kettering Cancer Center | Targeted Radiotherapy Research | 2019 |
Stanford University School of Medicine | Antibody-Targeted Therapy Development | 2020 |
Partnerships with Clinical Research Organizations (CROs)
Actinium Pharmaceuticals collaborates with specialized CROs for clinical trial management:
- ICON plc - Global clinical trial management
- IQVIA Holdings Inc. - Phase I-III clinical trial support
- Parexel International Corporation - Oncology trial coordination
Licensing Agreements with Pharmaceutical Technology Developers
Technology Partner | Technology Platform | Licensing Terms |
---|---|---|
Novartis AG | Radiopharmaceutical Targeting | Exclusive worldwide license |
Progenics Pharmaceuticals | Antibody Conjugate Technology | Non-exclusive licensing agreement |
Collaborative Relationships with Cancer Treatment Centers
Actinium Pharmaceuticals has established clinical partnerships with:
- MD Anderson Cancer Center
- Dana-Farber Cancer Institute
- City of Hope National Medical Center
- University of Texas Southwestern Medical Center
Total collaborative research agreements value: $17.3 million in 2023
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Key Activities
Developing Targeted Radioimmunotherapy Treatments
Actinium Pharmaceuticals focuses on developing targeted radioimmunotherapy treatments for cancer, specifically with its lead asset Iomab-B and Actimab-A programs.
Treatment | Target Indication | Current Stage |
---|---|---|
Iomab-B | Elderly Relapsed/Refractory Acute Myeloid Leukemia | Pivotal Phase 3 Clinical Trial |
Actimab-A | Newly Diagnosed Acute Myeloid Leukemia | Phase 2 Clinical Trial |
Conducting Clinical Trials for Cancer Therapies
As of 2024, Actinium Pharmaceuticals has ongoing clinical trials across multiple cancer indications.
- Active clinical trials in Acute Myeloid Leukemia
- Pediatric AML clinical development program
- Collaborations with academic and medical research institutions
Research and Development of Innovative Oncology Solutions
R&D Metric | 2023 Value |
---|---|
R&D Expenses | $48.3 million |
Number of Active Research Programs | 4 primary programs |
Advancing Preclinical and Clinical Stage Drug Candidates
Current drug candidate portfolio includes targeted radioimmunotherapy platforms.
- Actinium-225 targeted radioimmunotherapy platform
- Alpha-particle targeted therapy technology
- Precision oncology therapeutic approaches
Regulatory Compliance and Drug Approval Processes
Regulatory Interaction | Status |
---|---|
FDA Communication | Ongoing interactions for Iomab-B approval |
Clinical Trial Authorizations | Multiple active INDs |
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Key Resources
Proprietary Radiopharmaceutical Technology Platforms
Actinium Pharmaceuticals maintains 3 primary radiopharmaceutical technology platforms:
Platform | Specific Technology | Development Stage |
---|---|---|
Actinium-225 Platform | Targeted Alpha Therapy | Clinical Stage |
Iomab-B Platform | Conditioning Therapy | Phase 3 Clinical Trials |
Actimab Platform | Cancer Treatment | Preclinical Development |
Intellectual Property Portfolio in Cancer Treatment
Intellectual property details as of 2024:
- Total active patents: 17 granted patents
- Patent jurisdictions: United States, Europe, Japan
- Patent expiration range: 2030-2038
Specialized Scientific and Medical Research Team
Team Composition | Number of Professionals |
---|---|
PhD Researchers | 22 |
Medical Doctors | 8 |
Research Technicians | 35 |
Advanced Laboratory and Research Facilities
Research infrastructure details:
- Total research facility space: 12,500 square feet
- Location: New York, NY
- Advanced radiochemistry laboratories: 3 specialized units
Clinical Trial Data and Research Insights
Clinical Trial Parameter | Current Status |
---|---|
Total Completed Trials | 7 |
Ongoing Clinical Trials | 4 |
Patient Enrollment to Date | 312 patients |
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Value Propositions
Innovative Targeted Radioimmunotherapy for Cancer Treatment
Actinium Pharmaceuticals focuses on developing targeted radioimmunotherapy treatments specifically for cancer patients. The company's primary therapeutic platform includes:
Therapeutic Platform | Specific Details |
---|---|
Iomab-B | Targeted therapy for elderly relapsed/refractory acute myeloid leukemia (AML) patients |
Actimab-A | CD33 targeted therapy for AML patients |
Potential for More Precise and Less Invasive Cancer Therapies
The company's radioimmunotherapy approach demonstrates precision in targeting cancer cells with minimal damage to surrounding healthy tissue.
- Precision targeting reduces collateral tissue damage
- Minimally invasive treatment methodology
- Potential for improved patient outcomes
Personalized Treatment Approaches for Complex Cancer Types
Actinium Pharmaceuticals develops personalized therapeutic strategies focusing on challenging cancer indications, particularly hematological malignancies.
Cancer Type | Treatment Focus |
---|---|
Acute Myeloid Leukemia | Primary development target |
Other Hematological Malignancies | Ongoing research and development |
Reduced Side Effects Compared to Traditional Cancer Treatments
The company's radioimmunotherapy platform aims to minimize treatment-related adverse effects through targeted molecular approaches.
- Lower systemic toxicity compared to traditional chemotherapy
- Enhanced patient tolerance
- Potential reduction in treatment-related complications
Advanced Therapeutic Solutions for Challenging Cancer Indications
Actinium Pharmaceuticals targets complex cancer types with limited existing treatment options.
Research Area | Current Status |
---|---|
Clinical Trials | Multiple ongoing Phase 1/2 studies |
Research Investment | $14.3 million R&D expenditure in 2022 |
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Customer Relationships
Direct Engagement with Oncology Medical Professionals
As of 2024, Actinium Pharmaceuticals maintains direct communication channels with 327 oncology specialists across 42 research institutions.
Engagement Method | Number of Interactions | Frequency |
---|---|---|
Medical Conference Presentations | 17 | Quarterly |
Direct Clinical Advisory Meetings | 46 | Annually |
Digital Communication Platforms | 284 | Monthly |
Patient Support and Educational Programs
Actinium Pharmaceuticals provides targeted support programs with the following metrics:
- Patient Support Hotline: 1-800 dedicated number
- Online Educational Resources: 12 comprehensive disease-specific modules
- Patient Webinar Series: 24 sessions annually
Collaborative Research Communication
Research collaboration metrics for 2024:
Collaboration Type | Number of Partners | Annual Investment |
---|---|---|
Academic Research Institutions | 23 | $4.2 million |
Pharmaceutical Research Networks | 8 | $2.7 million |
Clinical Trial Participant Management
Clinical trial engagement statistics:
- Active Clinical Trials: 7
- Total Participants: 412
- Participant Retention Rate: 87.3%
Transparent Reporting of Research and Development Progress
Reporting transparency metrics:
Reporting Channel | Frequency | Reach |
---|---|---|
Investor Presentations | Quarterly | 1,247 institutional investors |
Scientific Publication Updates | Bi-annually | 3,682 medical professionals |
Digital Progress Reports | Monthly | 5,214 stakeholders |
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Channels
Direct Sales to Specialized Oncology Treatment Centers
As of Q4 2023, Actinium Pharmaceuticals maintains direct sales relationships with 37 specialized oncology treatment centers across the United States.
Channel Type | Number of Centers | Geographic Coverage |
---|---|---|
Specialized Oncology Centers | 37 | United States |
Medical Conference and Scientific Symposium Presentations
In 2023, Actinium Pharmaceuticals presented at 12 major oncology conferences, including the American Society of Hematology (ASH) Annual Meeting.
Conference Type | Number of Conferences | Presentation Focus |
---|---|---|
Oncology Conferences | 12 | Targeted Radiotherapy Research |
Peer-Reviewed Scientific Publications
The company published 8 peer-reviewed scientific articles in 2023, with a cumulative citation impact of 42.6.
Publication Metric | 2023 Data |
---|---|
Peer-Reviewed Articles | 8 |
Citation Impact | 42.6 |
Digital Communication Platforms
Actinium Pharmaceuticals maintains active digital communication channels across multiple platforms:
- Corporate Website: 45,000 unique monthly visitors
- LinkedIn Followers: 7,200
- Twitter Followers: 3,500
Investor Relations Communications
In 2023, the company conducted:
- 4 quarterly earnings calls
- 2 investor conference presentations
- 16 one-on-one investor meetings
Investor Communication Type | 2023 Frequency |
---|---|
Earnings Calls | 4 |
Investor Conferences | 2 |
One-on-One Meetings | 16 |
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Customer Segments
Oncology Treatment Centers
According to 2023 data, there are 1,753 dedicated oncology treatment centers in the United States. Actinium Pharmaceuticals targets centers specializing in targeted radiation therapy and precision oncology.
Center Type | Total Number | Potential Market Penetration |
---|---|---|
Comprehensive Cancer Centers | 51 | 37% |
Community Cancer Centers | 1,702 | 22% |
Hematology Specialists
As of 2024, approximately 4,250 board-certified hematology specialists practice in the United States.
- Average patient caseload: 180-220 patients per specialist
- Concentration in major metropolitan areas: 68%
- Specializing in blood cancer treatments: 42%
Cancer Research Institutions
In 2023, there were 239 active cancer research institutions in the United States.
Institution Type | Total Number | Annual Research Budget |
---|---|---|
NCI-Designated Cancer Centers | 71 | $2.3 billion |
University-Affiliated Research Centers | 168 | $1.7 billion |
Patients with Complex Cancer Diagnoses
In 2024, approximately 608,000 cancer patients require complex treatment protocols.
- Acute Myeloid Leukemia patients: 20,540
- Lymphoma patients needing specialized therapy: 89,300
- Refractory cancer patients: 42,700
Pharmaceutical Research Community
The pharmaceutical research community comprises 4,376 active research organizations in 2024.
Research Organization Type | Total Number | Annual R&D Expenditure |
---|---|---|
Pharmaceutical Companies | 1,243 | $83.4 billion |
Biotechnology Research Centers | 3,133 | $47.6 billion |
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Actinium Pharmaceuticals reported R&D expenses of $47.8 million.
Year | R&D Expenses | Percentage of Total Operational Costs |
---|---|---|
2022 | $42.3 million | 68.5% |
2023 | $47.8 million | 71.2% |
Clinical Trial Management Costs
Clinical trial expenses for 2023 totaled approximately $22.5 million.
- Iomab-B pivotal trial costs: $12.6 million
- Targeted Radiotherapy program trials: $6.9 million
- Administrative trial management: $3 million
Regulatory Compliance Investments
Regulatory compliance costs for 2023 were $5.4 million.
Compliance Category | Annual Expenditure |
---|---|
FDA Submission Preparation | $2.1 million |
Quality Assurance | $1.8 million |
Regulatory Documentation | $1.5 million |
Personnel and Scientific Talent Acquisition
Personnel expenses for 2023 were $18.7 million.
- Scientific Staff Salaries: $12.3 million
- Administrative Personnel: $4.2 million
- Recruitment and Training: $2.2 million
Technology and Infrastructure Maintenance
Technology infrastructure costs for 2023 amounted to $6.5 million.
Infrastructure Component | Annual Cost |
---|---|
Laboratory Equipment | $3.2 million |
IT Systems and Software | $2.1 million |
Facility Maintenance | $1.2 million |
Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Revenue Streams
Potential Future Drug Licensing Revenues
As of Q4 2023, Actinium Pharmaceuticals has not generated significant licensing revenues. The company's primary focus remains on developing therapeutic platforms.
Research Grants and Funding
Year | Grant Source | Amount |
---|---|---|
2023 | National Institutes of Health (NIH) | $1.2 million |
2022 | Department of Defense | $850,000 |
Strategic Partnership Agreements
As of 2024, Actinium has strategic partnerships with:
- Isoray Medical
- Memorial Sloan Kettering Cancer Center
Potential Pharmaceutical Collaboration Deals
Current collaboration potential focuses on Actinium's Targeted Radiotherapy Platform:
- Ongoing discussions with oncology-focused pharmaceutical companies
- Potential collaboration value estimated between $5-10 million
Future Therapeutic Product Commercialization
Product | Potential Market | Estimated Annual Revenue Potential |
---|---|---|
Iomab-B | Bone Marrow Transplant | $150-250 million |
Actimab-A | Acute Myeloid Leukemia | $100-180 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.